Nalmefene enhances the remyelinating ability of nalfurafine when administered therapeutically at very low doses during experimental autoimmune encephalomyelitis

Abstract Objectives Multiple sclerosis is an immune‐mediated inflammatory disease of the central nervous system. Recently, kappa opioid receptor (KOR) agonists were found to promote remyelination and recovery in models of demyelination. However, the side effects of many full KOR agonists limit clini...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Lisa Denny, Katharina Robichon, Nikki Templeton, Mackenzie Kiernan, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2025-01-01
Rangatū:	Clinical & Translational Immunology
Ngā marau:	experimental autoimmune encephalomyelitis kappa opioid receptor agonist mu opioid receptor antagonist nalfurafine nalmefene
Urunga tuihono:	https://doi.org/10.1002/cti2.70069
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!